ERBB2 and breast carcinoma: In the EMILIA study, T-DM1 exhibited improved survival for the second-line treatment of metastatic HER2-positive breast cancer compared to the existing standard therapy, capecitabine with lapatinib, a HER2 tyrosine kinase inhibitor [23].